{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:13:17Z","timestamp":1775236397479,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"2-5","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.jsbmb.2005.02.004","type":"journal-article","created":{"date-parts":[[2005,4,9]],"date-time":"2005-04-09T07:57:04Z","timestamp":1113033424000},"page":"237-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Are aromatase inhibitors superior to antiestrogens?"],"prefix":"10.1016","volume":"93","author":[{"given":"Anthony","family":"Howell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aman","family":"Buzdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2005.02.004_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib2","first-page":"525","article-title":"Adrenalectomy and oophorectomy in the treatment of advanced carcinoma of the breast","volume":"151","author":"Huggins","year":"1953","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/1097-0142(197307)32:1<31::AID-CNCR2820320104>3.0.CO;2-5","article-title":"Preliminary result of aminoglutethimide in breast cancer","volume":"32","author":"Griffiths","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1677\/erc.0.0060235","article-title":"The potential of aromatase inhibitors in breast cancer prevention","volume":"6","author":"Santen","year":"1999","journal-title":"Endocrinol. Relat. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","article-title":"Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study","volume":"20","author":"Geisler","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib6","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/S0959-8049(03)00630-0","article-title":"An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole","volume":"39","author":"Rose","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2005.02.004_bib7","first-page":"6","article-title":"On behalf of the IMPACT trialists, comparison of anastrozole versus tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial","volume":"82","author":"Smith","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/141247b0","article-title":"Oestrogenic activity of certain synthetic compounds","volume":"141","author":"Dodds","year":"1938","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib9","doi-asserted-by":"crossref","unstructured":"J.M. Robson, A. Schonber, Oestrous reactions, including mating, produced by triphenylethylene, Nature 140:1996, 1937.","DOI":"10.1038\/140196b0"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/bmj.2.4368.393","article-title":"Influences of synthetic oestrogens upon advanced malignant disease","volume":"2","author":"Haddow","year":"1944","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"Lonning","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-ooestrogenic agent in breast cancer: an early clinical appraisal of ICI 146474","volume":"25","author":"Cole","year":"1971","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beem.2003.08.002","article-title":"The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer","volume":"18","author":"Howell","year":"2004","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance","volume":"2","author":"Ali","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(95)91156-1","article-title":"Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer","volume":"345","author":"Howell","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1008226721932","article-title":"Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer","volume":"9","author":"Gershanovich","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib20","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib22","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib23","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib24","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0959-8049(03)00326-5","article-title":"Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results","volume":"39","author":"Nabholtz","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0960-0760(03)00374-1","article-title":"Advanced breast cancer updates on anastrozole versus tamoxifen","volume":"86","author":"Nabholtz","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.COC.0000047126.10522.F9","article-title":"Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study","volume":"26","author":"Milla-Santos","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib28","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib29","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","article-title":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1359-6349(04)90844-0","article-title":"First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC","volume":"Suppl. 2","author":"Paridaens","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib32","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib33","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib34","first-page":"350","article-title":"A randomized trial of exemestane after 2\u20133 years of tamoxifen therapy in postmenopausal women with primary breast cancer","author":"Coombes","year":"20041081","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib35","doi-asserted-by":"crossref","unstructured":"F. Boccardo, A. Rubagotti, P. Guglielmini, D. Amoroso, A. Fini, G. Paladini, M. Mesiti, D. Romeo, M. Rinaldini, S. Scali, M. Porpiglia, C. Benedetto, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial, N. Engl. J. Med. (2004), submitted for publication.","DOI":"10.1200\/JCO.2005.04.120"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib36","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib37","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than 5 years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumours","volume":"88","author":"Fisher","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than 5 years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib39","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/cncr.10908","article-title":"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane","volume":"95","author":"Buzdar","year":"2002","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2005.02.004_bib40","first-page":"S31","article-title":"Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer","volume":"82","author":"Sawada","year":"2003","journal-title":"Br. Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1359-6349(04)90900-7","article-title":"Anastrozole therapy and lipid profile: an update","volume":"2","author":"Wojtacki","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib42","unstructured":"J. Wojtacki, K. Lesniewski-Kmak, W.J. Kruszewski, Anastrozole therapy does not compromise lipid metabolism in breast cancer patients previously treated with tamoxifen. Breast Cancer Res. Treat. 76 (Suppl. 1): S75, (abstract 262)."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib43","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/annonc\/mdh064","volume":"15","author":"Atalay","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00713400","article-title":"Plasma changes in breast cancer patients during endocrine therapy\u2014lipid measurements and nuclear magnetic resonance (NMR) spectroscopy","volume":"36","author":"Engan","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib45","first-page":"43a","volume":"20","author":"Lohrisch","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2005.02.004_bib46","first-page":"105","article-title":"The effect of exemestane (Aromasin) on the lipidemic profile of breast cancer patients: preliminary results of the TEAM trial Greek sub-study","volume":"82","author":"Markopoulos","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib47","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0959-8049(01)00155-1","article-title":"Effect of letrozole on the lipid profile in postmenopausal women with breast cancer","volume":"37","author":"Elisaf","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib48","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1093\/annonc\/mdf083","article-title":"Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism","volume":"13","author":"Bajetta","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1359\/jbmr.2002.17.1.172","article-title":"Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women","volume":"17","author":"Heshmati","year":"2002","journal-title":"J. Bone Min. Res."},{"issue":"Suppl. 5","key":"10.1016\/j.jsbmb.2005.02.004_bib50","first-page":"32","article-title":"Results of the \u2019Arimidex\u2019 (anastrozole, A), tamoxifen (T), alone or in combination (C) (ATAC) trial: Effects on bone mineral density (BMD) and bone turnover (ATAC trialists\u2019 Group)","volume":"13","author":"Eastell","year":"2002","journal-title":"Ann. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2005.02.004_bib51","first-page":"27","article-title":"Effect of anastrozole on bone mineral density: 2-year results of the arimidex (anastrozole), tamoxifen, alone or in combination (ATAC) trial","volume":"82","author":"Howell","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib52","first-page":"25","article-title":"The time course of bone fractures observed in the ATAC (arimidex, tamoxifen, alone or in combination) trial","volume":"22","author":"Locker","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2005.02.004_bib53","first-page":"101","article-title":"Effects of steroidal and non-steroidal aromatase inhibitors on markers of bone turnover and lipid metabolism in healthy volunteers","volume":"82","author":"Goss","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib54","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2003.04.596","article-title":"Amercian Society of Clinical Oncology Technology Group Update: Use of aromatase inhibitors in the adjuvant setting","volume":"21","author":"Winer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib55","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/jnci\/88.24.1834","article-title":"Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged 50 years or older with breast cancer","volume":"88","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib56","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomized trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2005.02.004_bib57","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib58","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMe038167","article-title":"Letrozole after tamoxifen for breast cancer\u2014what is the price of success?","volume":"349","author":"Bryant","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib59","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMe048037","article-title":"New stars in the sky of treatment for early breast cancer","volume":"350","author":"Piccart-Gebhart","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib60","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/bmj.321.7263.745","article-title":"ABC of breast diseases: breast cancer","volume":"321","author":"Sainsbury","year":"2000","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3322\/canjclin.47.1.28","article-title":"Tumor-related prognostic factors for breast cancer, CA","volume":"47","author":"Donegan","year":"1997","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1677\/erc.0.0060227","article-title":"Lessons from the aromatase inhibitors in the adjuvant setting","volume":"6","author":"Dixon","year":"1999","journal-title":"Endocrine Rel. Ca."},{"key":"10.1016\/j.jsbmb.2005.02.004_bib63","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","article-title":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and\/or ErbB-2 positive estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial","volume":"19","author":"Ellis","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"Suppl.","key":"10.1016\/j.jsbmb.2005.02.004_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1359-6349(04)90650-7","article-title":"Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials","volume":"2","author":"Smith","year":"2004","journal-title":"Eur. J. Cancer"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076005000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076005000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:51:03Z","timestamp":1760734263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076005000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":64,"journal-issue":{"issue":"2-5","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0960076005000609"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2005.02.004","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are aromatase inhibitors superior to antiestrogens?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2005.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}